Abstract
MiRNAs play a relevant role in PC (prostate cancer) by the regulation in the expression of several pathways’ AR (androgen receptor), cellular cycle, apoptosis, MET (mesenchymal epithelium transition), or metastasis. Here, we report the role of several miRNAs’ expression patterns, such as miR-93-5p, miR-23c, miR-210-3p, miR-221-3p, miR-592, miR-141, miR-375, and miR-130b, with relevance in processes like cell proliferation and MET. Using Trizol® extraction protocol and TaqMan™ specific probes for amplification, we performed miRNAs’ analysis of 159 PC fresh tissues and 60 plasmas from peripheral blood samples. We had clinical data from all samples including PSA, Gleason, TNM, and D’Amico risk. Moreover, a bioinformatic analysis in TCGA (The Cancer Genome Atlas) was included to analyze the effect of the most relevant miRNAs according to aggressiveness in an extensive cohort (n = 531). We found that miR-210-3p, miR-23c, miR-592, and miR-93-5p are the most suitable biomarkers for PC aggressiveness and diagnosis, respectively. In fact, according with our results, miR-93-5p seems the most promising non-invasive biomarker for PC. To sum up, miR-210-3p, miR-23c, miR-592, and miR-93-5p miRNAs are suggested to be potential biomarkers for PC risk stratification that could be included in non-invasive strategies such as liquid biopsy in precision medicine for PC management.
Highlights
Current medicine is focused on precision medicine, with the aim of providing better management and treatment of patients in several diseases like cancer
The Cancer Genome Atlas (TCGA) analysis reported several top miRNAs as up-regulated and down-regulated with effect in PC aggressiveness according to Gleason Score
We developed two main comparisons, selecting samples with reported paired results reported in a healthy area (G0)
Summary
Current medicine is focused on precision medicine, with the aim of providing better management and treatment of patients in several diseases like cancer. Biomedicines 2021, 9, 646 strategies for disease detection, diagnosis, prognosis, prediction of response to intervention, and disease monitoring. PC is one of the most prevalent (incidence of 37.5 per 100,000) tumors among men in the world after lung cancer and the second most frequent cause of cancer-related death (375,000 deaths worldwide) [1] It accounts for around the 20% of newly diagnosed cancers, according to 2020 cancer statistics [2]. Exosomebased biomarkers have quickly become adopted in the clinical arena and the first PC exosome RNA-based test has already helped >50,000 patients in decision processes. As a result, it is included in the National Comprehensive Cancer Network (NCCN)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
